Results for tag: "Duaklir Pressair"

The Duaklir Pressair market is a segment of the respiratory drug market that focuses on the treatment of chronic obstructive pulmonary disease (COPD). It is composed of long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs) that are used in combination to reduce symptoms and improve lung function. These drugs are typically administered via inhalers and are used to reduce airway inflammation and improve airflow. Duaklir Pressair is a combination of two drugs, aclidinium bromide and formoterol fumarate dihydrate, which are both long-acting bronchodilators. Aclidinium bromide is a LAMA that works by blocking the muscarinic receptors in the airways, while formoterol fumarate dihydrate is a LABA that works by stimulating the beta-2 receptors in the airways. The Duaklir Pressair market is a growing segment of the respiratory drug market, with many companies offering products. Some of these companies include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more